Agios Pharmaceuticals, Inc. - Common Stock (AGIO)
Frequently Asked Questions About Agios Pharmaceuticals, Inc. - Common Stock (AGIO)
How does Agios Pharmaceuticals contribute to the community?
Agios Pharmaceuticals is committed to corporate social responsibility by supporting initiatives that enhance community health and education. The company engages in collaborations with healthcare providers, supports research opportunities, and invests in various programs aimed at improving health outcomes and increasing awareness around the diseases they address.
How does Agios Pharmaceuticals ensure patient safety?
Agios Pharmaceuticals places a high priority on patient safety throughout its research and development process. The company adheres to stringent regulatory guidelines for clinical trials, conducts comprehensive safety assessments, and monitors adverse events to ensure that any risk to patients is minimized while maximizing therapeutic benefit.
How does Agios Pharmaceuticals handle drug development?
Agios Pharmaceuticals employs a rigorous drug development process that involves extensive preclinical studies, clinical trials, regulatory submissions, and post-marketing surveillance to ensure the safety and efficacy of its medicines. The company emphasizes scientific integrity and compliance with regulatory standards throughout the development lifecycle to bring innovative solutions to market.
What are Agios Pharmaceuticals’ key products?
Agios Pharmaceuticals has developed several key products, including Idhifa (enasidenib) approved for treating relapsed or refractory acute myeloid leukemia (AML) and Tibsovo (ivosidenib) for treating AML with a specific genetic mutation. These products underscore Agios's commitment to addressing unmet medical needs through innovative therapeutic solutions.
What are the recent developments for Agios Pharmaceuticals?
Agios Pharmaceuticals continually experiences developments in its clinical and corporate landscape, including advancements in ongoing clinical trials, regulatory approvals, and potential licensing deals. These developments represent the company's progress toward delivering innovative therapies and reflect its commitment to growth in the biopharmaceutical industry.
What does Agios Pharmaceuticals, Inc. do?
Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing innovative therapies for cancer and rare genetic diseases. The company leverages its unique expertise in metabolic pathways to target disease processes, thereby providing new treatment options that significantly improve the lives of patients. Agios is dedicated to advancing its proprietary products and collaborations to bring impactful solutions to the healthcare landscape.
What is Agios Pharmaceuticals, Inc.'s stock symbol?
Agios Pharmaceuticals, Inc. is publicly traded on the Nasdaq stock exchange under the symbol AGIO. This enables investors to buy and sell shares of the company, providing the necessary capital for ongoing research and development efforts.
What is Agios Pharmaceuticals’ approach to innovation?
Agios Pharmaceuticals fosters a culture of innovation by integrating cutting-edge science with an entrepreneurial mindset. The company encourages creative problem-solving and collaborative research initiatives to explore new therapeutic strategies, enabling it to stay at the forefront of advances in metabolic therapy.
What is the market focus of Agios Pharmaceuticals?
Agios Pharmaceuticals primarily focuses on the oncology market, targeting cancers characterized by specific genetic mutations as well as rare genetic disorders. This includes both hematologic malignancies and solid tumors, where there are significant unmet needs for effective therapies tailored to unique patient populations.
What is the significance of metabolic pathways in Agios Pharmaceuticals’ research?
Metabolic pathways are central to Agios Pharmaceuticals' research, as they play a crucial role in cancer and other diseases. By understanding how these pathways are altered in disease, Agios aims to identify novel treatment targets and develop therapies that can effectively disrupt disease progression while sparing healthy tissue, thereby enhancing the safety and efficacy of treatments.
What is the status of Agios Pharmaceuticals' clinical trials?
Agios Pharmaceuticals actively conducts clinical trials as part of its robust pipeline aimed at evaluating its drug candidates in treating various cancers and rare genetic diseases. The trials are designed to assess the safety and efficacy of their therapeutics, and updates regarding trial status and outcomes are regularly communicated to investors and the public.
What is the vision and mission of Agios Pharmaceuticals?
Agios Pharmaceuticals' vision is to pioneer the field of metabolic therapy with the goal of transforming the lives of patients suffering from serious diseases. The company’s mission is to harness insights into metabolic pathways to create and deliver innovative medicines that fulfill unmet therapeutic needs, particularly in the areas of oncology and rare genetic disorders.
What kind of therapies does Agios Pharmaceuticals develop?
Agios Pharmaceuticals specializes in developing therapies across hematologic malignancies and solid tumors, as well as treatments for rare genetic diseases like pyruvate kinase deficiency. Their pipeline includes novel small molecules and gene therapies that target metabolic processes critical to cancer progression and disease pathophysiology.
What partnerships does Agios Pharmaceuticals have?
Agios Pharmaceuticals has established strategic collaborations with various organizations, including partnerships with other biopharmaceutical companies and research institutions. These collaborations enhance Agios's development capabilities and extend its reach in discovering new therapies, facilitating access to additional resources and expertise.
What pipeline products are in development at Agios Pharmaceuticals?
Agios Pharmaceuticals boasts a diverse pipeline with multiple drug candidates in various stages of clinical development. This includes investigational therapies for genetic disorders and ongoing research into new applications of existing therapies aimed at enhancing treatment options and outcomes for patients diagnosed with difficult-to-treat conditions.
When was Agios Pharmaceuticals, Inc. founded?
Agios Pharmaceuticals, Inc. was founded in 2008. Since its inception, the company has focused on leveraging metabolic biology to create novel treatments, and it has made significant strides in drug development and clinical research in the years following its establishment.
Where is Agios Pharmaceuticals, Inc. located?
Agios Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts. The location places the company in the heart of an innovative biotech hub, allowing access to a extensive network of expertise, partnerships, and investment opportunities that further fuel its research and development activities.
Who are Agios Pharmaceuticals' leadership team members?
Agios Pharmaceuticals has a skilled leadership team comprising experienced professionals from both scientific and business backgrounds. The team includes Chief Executive Officer, Chief Financial Officer, and various other executives overseeing research, development, commercial activities, and operations, all committed to driving the company's mission and vision.
What is the current price of Agios Pharmaceuticals, Inc. - Common Stock?
The current price of Agios Pharmaceuticals, Inc. - Common Stock is 36.50
When was Agios Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Agios Pharmaceuticals, Inc. - Common Stock was at 4:00 pm EDT on September 11th, 2025
What is the market capitalization of Agios Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Agios Pharmaceuticals, Inc. - Common Stock is 2.15B
How many shares of Agios Pharmaceuticals, Inc. - Common Stock are outstanding?
Agios Pharmaceuticals, Inc. - Common Stock has 58.95M shares outstanding.